Anthem clarified coverage for bevacizumab in hepatocellular carcinoma (HCC) effective 2026-03-01, reaffirming use only in combination with atezolizumab for unresectable or metastatic HCC consistent with the FDA label. Coverage aligns with NCCN guidance, specifying eligibility for patients with Child-Pugh Class A or B liver function and ECOG performance status 0–2. The combination is supported as first-line therapy and may also be used as subsequent systemic therapy consistent with NCCN 2A designation, and bevacizumab may be continued until disease progression. The policy maps multiple bevacizumab products and biosimilars to the HCC indication to ensure consistent application across formulations.
March 2026 Revision: Bevacizumab for HCC Clarified
Summary of changes in this revision
This policy (CC-0107) effective 2026-03-01 reiterates and clarifies coverage criteria for use of bevacizumab in hepatocellular carcinoma (HCC) as described in the document. The revision maintains the FDA-approved combination use of bevacizumab with atezolizumab for unresectable or metastatic HCC in patients who have not received prior systemic therapy, and aligns with NCCN guidance by specifying Child-Pugh class and performance status requirements. The history shows prior updates (notably 06/08/2020 and 05/15/2020) added and updated criteria for HCC; the current effective date indicates consolidation of those prior references into the present criteria.
The document history entries emphasize ongoing alignment with NCCN and FDA actions over multiple reviews (2020–2022). The policy continues to reference both the FDA label and NCCN categories (e.g., NCCN 1 and NCCN 2A) when defining acceptable uses and sequencing (first-line and subsequent systemic therapy) of bevacizumab in combination with atezolizumab for HCC.
Label and Guideline Alignment for Unresectable/Metastatic HCC
Approved indication and clinical context for HCC
The policy states that bevacizumab is FDA approved in combination with atezolizumab for treatment of unresectable or metastatic hepatocellular carcinoma in individuals who have not received prior systemic therapy. This is the labeled indication and is explicitly referenced in the policy text.
In addition to the FDA label, the policy cites NCCN guidance that considers the atezolizumab–bevacizumab combination a preferred first-line treatment for individuals with Child-Pugh Class A or B liver function, noting the NCCN preference is based on the clinical trial population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.